Systems and methods for detecting watermark formations on semiconductor wafers
    2.
    发明授权
    Systems and methods for detecting watermark formations on semiconductor wafers 失效
    用于检测半导体晶片上的水印构造的系统和方法

    公开(公告)号:US08580696B2

    公开(公告)日:2013-11-12

    申请号:US11829581

    申请日:2007-07-27

    IPC分类号: H01L21/302

    CPC分类号: H01L21/67253

    摘要: Systems and methods for detecting watermark formations on semiconductor wafers are described. In one embodiment, a method comprises providing a semiconductor wafer having at least one watermark sensitive region fabricated thereon, subjecting the wafer to a wet processing step, enhancing a susceptibility to detection of at least one watermark formation created on the at least one watermark sensitive region, and detecting the at least one watermark formation. In another embodiment, a method comprises growing a first oxide layer on a surface of a semiconductor wafer, patterning a watermark sensitive structure on the first oxide layer, depositing a silicon layer over the first oxide layer, doping a region of the silicon layer over the watermark sensitive structure with an impurity to create a watermark sensitive region that is prone to retaining watermark formations as result of a wet processing step, and growing a second oxide layer over the silicon layer.

    摘要翻译: 描述了用于检测半导体晶片上的水印结构的系统和方法。 在一个实施例中,一种方法包括提供具有在其上制造的至少一个水印敏感区域的半导体晶片,对晶片进行湿处理步骤,增强对至少一个水印敏感区域上产生的至少一个水印形成的检测的敏感性 并且检测所述至少一个水印形成。 在另一个实施例中,一种方法包括在半导体晶片的表面上生长第一氧化物层,在第一氧化物层上构图水印敏感结构,在第一氧化物层上沉积硅层,将硅层的区域掺杂在 具有杂质的水印敏感结构,以产生湿式处理步骤结果易于保留水印结构的水印敏感区域,并在硅层上生长第二氧化物层。

    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL

    公开(公告)号:US20130137122A1

    公开(公告)日:2013-05-30

    申请号:US13747646

    申请日:2013-01-23

    IPC分类号: G01N33/68

    摘要: A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

    NGAL FOR REDUCTION AND AMELIORATION OF ISCHEMIC AND NEPHROTOXIC INJURIES
    4.
    发明申请
    NGAL FOR REDUCTION AND AMELIORATION OF ISCHEMIC AND NEPHROTOXIC INJURIES 失效
    减少和改善化疗和非传染性创伤的NGAL

    公开(公告)号:US20100254970A1

    公开(公告)日:2010-10-07

    申请号:US12817566

    申请日:2010-06-17

    IPC分类号: A61K38/48 A61P13/12

    摘要: Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.

    摘要翻译: 使用嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL)作为治疗剂,以及将治疗,减少或改善选自缺血性损伤,缺血再灌注损伤和毒素诱导的损伤的损伤的方法应用于 患者。 本发明包括以有效治疗,减轻或改善对器官(例如肾)的缺血性,缺血再灌注或毒素诱导的损伤的量向患者NGAL施用。 铁载体可与NGAL共同施用。 本发明还涉及在对患者的器官的缺血或毒素诱导的损伤之后施用形象以增强对NGAL分泌的反应。

    NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
    5.
    发明授权
    NGAL for reduction and amelioration of ischemic and nephrotoxic injuries 有权
    NGAL用于减少和改善缺血性和肾脏损伤

    公开(公告)号:US07776824B2

    公开(公告)日:2010-08-17

    申请号:US11123364

    申请日:2005-05-06

    IPC分类号: A61K38/04 A01N1/00 A01N1/02

    摘要: Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.

    摘要翻译: 使用嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL)作为治疗剂,以及将治疗,减少或改善选自缺血性损伤,缺血再灌注损伤和毒素诱导的损伤的损伤的方法应用于 患者。 本发明包括以有效治疗,减轻或改善对器官(例如肾)的缺血性,缺血再灌注或毒素诱导的损伤的量向患者NGAL施用。 铁载体可与NGAL共同施用。 本发明还涉及在对患者的器官的缺血或毒素诱导的损伤之后施用形象以增强对NGAL分泌的反应。

    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL

    公开(公告)号:US20100184089A1

    公开(公告)日:2010-07-22

    申请号:US12750241

    申请日:2010-03-30

    IPC分类号: G01N33/573 G01N33/566

    摘要: A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

    Inverter apparatus with improved gate drive for power MOSFET
    9.
    发明授权
    Inverter apparatus with improved gate drive for power MOSFET 有权
    用于功率MOSFET的改进的栅极驱动的逆变器装置

    公开(公告)号:US07551004B2

    公开(公告)日:2009-06-23

    申请号:US11337595

    申请日:2006-01-24

    IPC分类号: H03K3/00

    CPC分类号: H03K17/08122 H03K17/163

    摘要: An inverter apparatus is composed of a power MOSFET having a source/drain connected to an output terminal, and a gate drive circuit driving a gate of the power MOSFET. The gate drive circuit includes a discharging path connected with the gate of the power MOSFET. The discharging path includes a set of serially-connected diodes which are forward-connected in a direction of a discharge current from the gate of the power MOSFET.

    摘要翻译: 逆变器装置由具有与输出端子连接的源极/漏极的功率MOSFET和驱动功率MOSFET的栅极的栅极驱动电路构成。 栅极驱动电路包括与功率MOSFET的栅极连接的放电路径。 放电路径包括一组串联连接的二极管,其在来自功率MOSFET的栅极的放电电流的方向上正向连接。

    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL

    公开(公告)号:US20080090304A1

    公开(公告)日:2008-04-17

    申请号:US11770245

    申请日:2007-06-28

    IPC分类号: G01N33/53 G01N33/68

    摘要: A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.